Innovative Approaches to Investigating KRAS Therapeutics with Biochemical and Cell-Based Assays
(June 15, 2022)
Kirsten rat sarcoma viral oncogene homologue (KRAS) is the most frequently mutated oncogene, present in approximately 25% of tumors. Numerous studies on KRAS in the initiation and advancement of cancer are constantly updating our knowledge of the gene. Despite drug-targeting attempts over the past four decades, KRAS has been labeled a difficult therapeutic target, even “”undruggable”, however, recent advances, such as the FDA approval of Amgen’s sotorasib, exemplifies and encourages new progress in the field.
This webinar explores innovative methods to discover and qualify KRAS inhibitors with downstream signaling and binding assays, utilizing no-wash HTRF® and AlphaLISA® technology to further the discovery of drugs targeting KRAS.
What You Will Learn:
• How to screen compounds with binding to identify positive hits and competitors
• Detection of MAPK activation to evaluate the efficacy and potency of KRAS inhibitors
• Data supporting indirect targeting of KRAS inhibitors with the RAF MEK approach and direct targeting of KRAS SOSI and KRAS G12 inhibitors